Daiichi Sankyo and AstraZeneca’s (AZN) supplemental biologics license application for Enhertu in combination with pertuzumab has been accepted and granted priority review in the U.S. for the first-line treatment of adult patients with unresectable or metastatic HER2 positive breast cancer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- Burning Rock announces OncoGuide OncoScreen Plus CDx System approval in Japan
- Sophia Genetics expands collaboration with AstraZeneca
- AstraZeneca, Amgen’s Tezspire recommended for approval in EU
- AstraZeneca’s Koselugo has been recommended for approval in EU
- AstraZeneca’s Latest Study on Budesonide-Formoterol: Key Insights for Investors